Current clinical therapy for Pompe disease is enzyme replacement therapy (ERT) which systemically delivers the recombinant human GAA (rhGAA) to break-down accumulated glycogen. The gene discussed is GAA; the disease is Glycogen storage disease due to acid maltase deficiency.